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Abstract
Background: Primary cutaneous lymphomas (CLs), characterized by an accumulation of clonal T or B lymphocytes
preferentially localized in the skin, have been successfully treated with interferons (IFNs) which counterbalance the
Th2-immunosuppressive state associated with this pathology. In a phase I/II clinical trial, we correlated the local
immune infiltrate and the anti-tumor effects of repeated intralesional administrations of an adenovirus vector
expressing human interferon-gamma (IFN-g) termed TG1042, in patients with advanced primary cutaneous T-cell
lymphomas (CTCL) or multilesional cutaneous B-cell lymphomas (CBCL).
Methods: For each patient, variation in time of specific lymphocyte populations, defined by immunohistochemical
stainings, was assessed in biopsies of injected lesions. For each patient, the change in local immune response was
associated with the patient’s objective response at the end of the study.
Results: Immunohistochemical analyses of biopsies indicate that infiltration of CD8+ T lymphocytes and of TIA-1+
cytotoxic T-cells in lesions injected with TG1042 correlates with clinical benefit.
Conclusions: These data suggest for the first time that a CD8+ cytotoxic infiltrate, induced by local expression of
IFN-g correlates with a clinical response.
Trial registration: The phase I step (TG1042.01) does not have a registration number. The phase II step (TG1042.06)
registration number was NCT00394693.
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Background
Cutaneous lymphoma (CL), with an incidence of 1 case
per 100,000 individuals per year, is a group of at least
fifteen rare diseases [1]. CL span a wide array of clinical
aspects and histological subtypes which correspond to
clonal T or B cells, characterized by their expression of
lymphoid cell markers, homing and migrating mainly
in the skin [2]. In CTCL, the CD4/CD8 ratio has been
associated with the tumor stage of the disease [3]. The
granulomatous slack skin is an extremely rare subtype
of MF characterized by epidermal focal infiltration of
small atypical T cells with a CD3+, CD4+, CD8- phenotype
[4]. Large T-cell CD30+ lymphoma (ALCL) demonstrate
diffuse infiltrates of large anaplastic CD30+ T cells which
are CD4+ with variable loss of the pan-T-cell antigen CD3
[5], [6]. The atypical cells in the lymphomatoid papulosis
types A and C lesions have the same phenotype as the
tumor cells in ALCL. The type B lesions have a CD3+,
CD4+, CD8-, CD30- phenotype [4]. Pleomorphic small/
medium-sized T-cell lymphoma is characterized by atyp-
ical lymphoid cells expressing the CD4 molecule [5,7].
B-cell lymphomas are characterized by a dense infiltrate
of tumor cells expressing B cell-specific surface antigens
such as CD20 and CD79α [8,9]. In summary, the CD4
marker is characteristic of cutaneous T-cell lymphomas
(CTCL) and the CD20 and CD79α markers are features
of cutaneous B-cell lymphomas (CBCL).
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The body of information now encompassing this
family of diseases has motivated the development and
justified the use of numerous treatment modalities such
as kinase, methylation or histone acetylation inhibitors,
mAbs, rexinoids and photopheresis [10]. Disease pro-
gression is associated with a decrease in the production
of Th1 cytokines and a shift towards the anti-inflammatory
Th2 phenotype and some of the successful treatments
have been shown to restore the Th1/Th2 imbalance [11].
Moreover, this group of diseases has been successfully
treated with interferons and cytokines that counterbalance
the Th2-skewing [12-14].
IFN-g is the principal cytokine associated with the Th1
phenotype. It acts in a positive feedback loop as it is pro-
duced by activated Th1 cells and stimulates differenti-
ation of Th0 cells into Th1 cells while suppressing Th2
differentiation (reviewed in [15]). However, using IFN-g
to treat pathologies resulting from a Th1/Th2 imbalance
is hampered by the significant side effects associated with
systemic administration of recombinant cytokines along
with their short half-life. This has led to the development
of alternative delivery systems such as TG1042, a non-
replicating adenovirus type 5 vector containing a human
IFN-g cDNA insert under the control of the cytomegalo-
virus promoter [16]. Intralesional delivery of human
IFN-g-expressing adenovirus allows reaching high local
concentrations of this cytokine, as shown by quantita-
tive RT-PCR in 7 out of 9 patients following the first
treatment cycle. The concentrations reached induce
lymphocytic infiltration and activation of local effector
cells [16]. We have developed and used TG1042 in
clinical trials in CLs [16,17]. The work presented here
describes the changes in the infiltrates throughout treat-
ment, consisting in repeated intratumoral injections of
TG1042, in patients that participated in these phase I/II
clinical trials using extensive immunohistochemistry phe-
notyping. Our results show that patients whom responded
favourably after intralesional injections of TG1042
had an increase in the frequency of CD8+ cells and
T-cell-restricted intracellular antigen (TIA-1 or cytotoxic
granule-associated RNA binding protein) positive cyto-
toxic cells relative to baseline levels. These results are
indicative that the immune reaction is a critical compo-
nent in the antitumor response in lymphoma.
Materials and methods
Thirty patients with advanced primary CTCL or multi-
lesional CBCL were enrolled in the phase I step (cohort
4 – Patients 10 to 18) and in the phase II step (cohort
5 – Patients 19 to 39) of the clinical studies supported
by Transgene S.A. (Strasbourg France). The study was
approved by the local institutional ethical committees
and the national authorities for biosafety in Switzerland,
Germany, and France, and conducted in accordance with
the ethical principles of the Declaration of Helsinki, in
compliance with the approved protocol, and its amend-
ments, and good clinical practices. Patients received re-
peated intratumoral administration of TG1042 (3E + 11
viral particles (vp) per injection, divided in up to three
lesions). Among these 30 patients, 20 were evaluable for
efficacy. In this latter population, 19 patients were assessed
for the nature of the lymphocytic infiltrate in skin biopsies
by immunohistochemistry at different time points through-
out the study (for Phase I and Phase II details, refer to
[16,17]). Details of each patient in the study population,
including histological type and stage are given in Table 1.
In both cohorts, patients received intratumoral injec-
tions of TG1042 in the same lesions on days 1, 8 and 15
of each cycle (for details please refer to [16,17]). Patients
did not receive treatment the fourth week. Each cycle
lasted 4 weeks and response to treatment was evaluated
by measuring tumor surfaces at baseline and at the end
of each cycle. The local response was divided in four
categories: Complete Response (CR) was defined as the
absence of detectable residual disease; Partial Response
Table 1 Patient’s characteristics
Patient
#
Subtype1 Stage at
baseline
Biopsies2
10 FCBCL NA Baseline, C1
13 CD30+ ALCL IIB Baseline, C1
16 CD30+ ALCL IIA Baseline, C1, C2
17 GSS IB Baseline, C1, C2, C3, C4, C6, C9, C10
18 MF IIB Baseline, C1, C2
20 CD30+ ALCL IIB Baseline, C1
24 Pleomorphic CTCL IB Baseline, C1, C4, Last Visit
25 MF IB Baseline, C1, C4, Last Visit
27 MF IIB Baseline, C1
29 MF IB Baseline, C1, Last Visit
30 MF IB Baseline, C1, C4
31 MF IIB Baseline, C1, C4
33 DLBCL T3a Baseline, C1
34 MF IB Baseline, C1, Last Visit
35 MZBCL T3b Baseline, C1
36 MF IB Baseline, C1, C4
37 CD30+ ALCL IIB Baseline, C2
38 MF IB Baseline, C1, C4, Last Visit
39 MF IIB Baseline, C1, C3
Summary of relevant information for each patient analysed (patient number,
histology subtype, stage at baseline and time of biopsies sampling).
NA not applicable.
1Pathology subtypes: ALCL indicates anaplastic large cell lymphoma, MF
Mycosis fungoides, CBCL cutaneous B-cell lymphoma, DLBCL diffuse large
B-cell lymphoma, FCBCL follicle center B-cell lymphoma, MZBCL marginal
zone B-cell lymphoma, Pleomorphic CTCL Pleomorphic cutaneous T-cell
lymphoma, LyP lymphomatoid papulosis, GSS granulomatous slack skin.
2Cx: C:Cycle. x: cycle number at which the examined biopsies were sampled.
See Material and Methods for Cycle definition.
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(PR) was defined as a greater than 50% decrease in the
size of pre-existing lesions or if greater than 50% nodu-
lar or plaque-like lesions became macules without evi-
dence of internal involvement; Stable Disease (SD) was
defined as any response that did not meet the criteria
of complete response, partial response or Progressive
Disease (PD); the latter was defined as the appearance
of new lesions, an increase of 25% in the size of previ-
ously existing lesions, a change from macular to plaque-
like or nodular lesions in more than 25% of previously
existing lesions or any evidence for developing internal
manifestation. Patients showing CR or PR are considered
as responders while patients showing SD or PD are con-
sidered as non-responders. In absence of progressive
disease, patients received another cycle with a maximum of
12 cycles. Therapy was stopped when disease progressed
or when toxicity was noticed. Biopsies were collected at
Baseline (between days −14 and 0 relative to initiation of
the treatment), 24 hours after the third injection of a cycle
(noted Cx where x corresponds to the cycle number) or
at the last visit (noted Last Visit) corresponding to at
least 4 weeks after last TG1042 injection. When a CR
was observed, treatment was stopped and a biopsy was
taken (noted Cx). Table 1 summarizes the time of biop-
sies sampling for each patient.
Biopsies, corresponding to injection sites, were fixed
in formalin, embedded in paraffin and sectioned. Briefly,
formalin-fixed, paraffin embedded tissue sections were
deparaffinized in xylene and rehydrated in an ethanol/
water gradient. After epitope retrieval with antigen-specific
methods, endogenous peroxidases were inactivated and
non-specific staining was blocked by saturating sections
with 10% normal goat serum. Marker-specific primary
antibodies and their conditions of use are described in
Table 2. Sections were incubated for one and a half hour
at room temperature with primary antibodies diluted as
indicated in Table 2 in PBS or TBS. Revelation steps
were adapted for each primary antibody and applied for
30 minutes (Table 2). The horseradish peroxydase activ-
ity was visualized by diaminobenzidine (DAB) precipita-
tion (Dako). The revelation was standardized for each
marker. Slides were counterstained with hematoxylin
and mounted in Eukitt® (Labonord) after dehydration.
Staining was visualized using a Nikon Eclipse E800
microscope with 10x and 40x objectives and images were
acquired with a Nikon DXM1200 camera and the NIS-
Elements AR version 2.30 software (Nikon). For each pa-
tient and for each marker except MHC Class I, variations
in the number of infiltrated lymphocytes revealed by spe-
cific antibodies were first estimated by two independent
histologists (N.A. and N.M.). Since MHC Class I is present
on most cell types, we resorted to intensity variation es-
timates by visual appreciation. Results were tabulated to
estimate the evolution in time of each marker for one
patient. Four categories have been defined depending on
the increased, stable, decreased or absence of stained cell
between baseline and the last biopsy (Additional file 1:
Table S1). The proportions of positive cells were confirmed
on four patients, representative of various responses,
using in house-developed, ImageJ free software (http://
rsb.info.nih.gov/ij) macro-commands on entire section
scans (Nanozoomer, Hamamatsu). Commands quantify ob-
jects corresponding to DAB-positive cells and hematoxylin-
stained nuclei present in the whole infiltrating population.
The results are given as percentage of positive cells on total
nuclei (Figures 1, 2, 3 and 4).
Results
We analyzed the nineteen patients at the indicated time-
points and estimated the levels of expression of CD3,
CD4, CD8, CD20cy, CD79αcy, MHC Class I and TIA-1.
Additional file 1: Table S1 compiles the results.
Three of the four CTCL patients with a complete
response (CR) were CD30+ ALCL (#13, #16, and #20).
The pleomorphic CTCL patient (#24) also had a CR for
which the immune infiltrate is shown in Figure 1. These
patients showed an increase in the proportion of CD8+
cells between baseline and the last time point. The cyto-
toxic marker TIA-1 was increased or stable. The CD4+
lymphocytes, characteristic of CTCL, were either stable
or decreased in number.
Of the three evaluable MF CTCL partial responders
(PR) (#25, #31, and #36), one showed increase in the cel-
lular infiltrate while it remained unchanged for the two
other patients. All cases presented an increased propor-
tion of CD8+ lymphocytes in the biopsy and two patients
out of three showed an increased numbers of TIA-1+
and CD79α+ lymphocytes between baseline and the last
time point analyzed. Likewise, two patients out of three
showed increased numbers of CD3+ and CD4+ lymphocytes.
The six evaluable CTCL patients (#18 CD30+ ALCL,
#29 MF, #38 MF, #39 MF, #17 GSS and #37 CD30+
ALCL) with a stable disease (SD) had a stable or de-
creased frequency of CD3+ cells. Four out of six patients
had an increased frequency of CD8+ cells between base-
line and the last time point examined. The others markers
did not vary in a consistent way.
The three MF CTCL patients (#27 (Figure 2), #30, and
#34) with a progressive disease (PD) showed stable num-
bers of CD8+ lymphocytes (2/3) while the proportion of
CD3+ (3/3) or CD4+ lymphocytes (2/3) increased. One
patient showed stable numbers of TIA-1+ or CD79α+
lymphocytes, one patient showed a decreased number
of TIA-1+ cells and a stable number of CD79α+ lympho-
cytes, and one patient showed increased numbers of TIA-1+
or CD79α+ lymphocytes.
MHC Class I was evaluated using an intensity criterion
instead of the number of positive cells. One out of the
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Table 2 Antibodies used for immunohistochemical evaluation
Antibody Expression Clone Isotype Reference Source Antigen retrieval Dilution Amplification system
CD3 T-lymphocytes rabbit pc IgG A0452 DAKO EDTA buffer pH9
(Target Retrieval®, Dako)
1/100 0.5% dilution of horse biotinylated
secondary antibody + ABC amplification
system, Vector Laboratories
45 minutes - 95°C
CD4 helper and regulatory
T-lymphocytes
1 F6 mouse mc IgG1 NCL-CD4-1 F6 NOVOCASTRA 10 mM Citrate Buffer pH6 1/20 non diluted anti-mouse Envision®
system, Dako
4B12 mouse mc IgG1 κ NCL-CD4-368 NOVOCASTRA 3 x 5 minutes – 750 W 1/20 non diluted anti-mouse Envision®
system, Dako
CD8 cytotoxic T-lymphocytes C8/144B mouse mc IgG1κ #M7103 DAKO EDTA buffer pH9
(Target Retrieval®, Dako)
1/50 non diluted anti-mouse Envision®
system, Dako
45 minutes - 95°C
CD20cy mature and immature
B-lymphocytes
L26 mouse mc IgG2a κ M7055 DAKO 10 mM Citrate Buffer pH6 1/200 0.5% dilution of horse biotinylated
secondary antibody + ABC amplification
system, Vector Laboratories2 minutes - 750 W +
7 minutes -250 W
CD56 Natural Killer cells 564 mouse mc IgG2b NCL-CD56-504 NOVOCASTRA 10 mM Citrate Buffer pH6 1/50 non diluted anti-mouse Envision®
system, Dako
45 minutes – 95°C
CD79αcy B cells from early pre-B
to plasma cell stage and
neoplastic B-lymphocytes
HM57 mouse mc IgG1κ M7051 DAKO EDTA buffer pH9
(Target Retrieval®, Dako)
1/50 0.5% dilution of horse biotinylated
secondary antibody + ABC amplification
system, Vector Laboratories
45 minutes - 95°C
TIA-1 CD4 and CD8 positive
T cells, granulocytes,
monocytes and activated
NK cells
2G9 mouse mc IgG1 PN IM2550 IMMUNOTECH 10 mM Citrate Buffer pH6 1/50 non diluted anti-mouse Envision®
system, Dako
2 minutes - 750 W +
7 minutes -250 W
MHC Class I most nucleated cells HC10 mouse monoclonal
IgG2a
SB03 546 kindly provided by
Dr S. Ferrone,
G. Gaslini Institute, Italy
EDTA buffer pH9
(Target Retrieval®, Dako)
1/20 non diluted anti-mouse Envision®
system, Dako
45 minutes - 95°C.
MHC Class I: Major Histocompatibility Complex I (Human Leukocyte Antigen A, B, C); mc: monoclonal; pc: polyclonal; TIA-1: T-cell restricted intracellular antigen-1.
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Figure 1 Immune infiltrates in a CTCL complete responder before and after TG1042 treatment. Patient #24 at baseline (left panels) and at
last visit, 4 weeks after last TG1042 injection (right panels). Percentages on pictures correspond to the ratio of DAB-positive cells on total
hematoxylin-stained nuclei in the whole infiltrating population, as determined by ImageJ software macro-commands. The proportion of CD3 and
CD4 expressing cells decreased at the last timepoint; the number of CD8 and CD79 α expressing cells increased between baseline and last visit.
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Figure 2 Immune infiltrates in a CTCL progressive disease before and after TG1042 injections. Patient #27 at baseline (left panels) and at
C1D16 (right panels). Percentages on pictures correspond to the ratio of DAB-positive cells on total hematoxylin-stained nuclei in the whole
infiltrating population, as determined by ImageJ software macro-commands. The frequency of CD3 expressing cells increased between baseline
and C1D16; CD4, CD8 and TIA-1 were stable markers. (Insert) TIA-1 staining is associated with intracellular granules.
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Figure 3 Immune infiltrates in a CBCL complete responder before and after TG1042 injections. Patient #33 at baseline (left panels) and at
C1D16 (right panels). Percentages on pictures correspond to the ratio of DAB-positive cells on total hematoxylin-stained nuclei in the whole
infiltrating population, as determined by ImageJ software macro-commands. CD79α, CD20 and TIA-1 are stable markers; the frequency of CD8
expressing cells increased between baseline and C1D16.
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Figure 4 Immune infiltrates in a CBCL partial responder before and after TG1042 injections. Patient #35 at baseline (left panels) and at
C1D16 (right panels). Percentages on pictures correspond to the ratio of DAB-positive cells on total hematoxylin-stained nuclei in the whole
infiltrating population, as determined by ImageJ software macro-commands. The frequency of CD79α, CD20, CD8 or TIA-1 expressing cells
decreased between baseline and C1D16.
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seven evaluable CTCL responders (CR + PR) had in-
creased intensity of MHC Class I staining while the six
others were stable. Five out of the nine evaluable CTCL
non responders (SD + PD) had stable intensity of staining;
the others had increased (2/9) or decreased intensity (2/9).
The CBCL complete responders (#10 FCBCL and #33
DLBCL) showed an increased number of CD3+ and of
CD8+ lymphocytes between baseline and C1 associated
with an unchanged aspect of cellular infiltrate for patient
#33 (Figure 3). The cytotoxic marker TIA-1 was stable
or increased and the number of CD4+ cells was stable or
decreased. The MHC Class I staining intensity was stable
or increased.
The MZBCL partial responder (#35, Figure 4) showed a
smaller cellular infiltrate associated to a decreased number
of CD4+ and CD8+ lymphocytes between baseline and
C1D16. The MHC Class I staining intensity was stable.
In both type of responders, we observed a stable or
decreased number of CD20+ cells and CD79α+ cells,
characteristic of the pathology.
Discussion
Cutaneous lymphomas are neoplasms from the skin-
associated lymphoid tissue. Skin infiltrates of clonal CD3
positive, CD4 positive cells is characteristic of most cuta-
neous T-cell lymphomas (CTCL), whereas increased num-
bers of CD20 and CD79α positive cells in the skin are
features of cutaneous B-cell lymphomas (CBCL) [4].
CL depend on the presence of dominant Th2-type cy-
tokines in their microenvironment and immunotherapies
using IFN-a, IFN-g or IL-12 have antitumor activity [11,18].
Mechanistically, IFN-g inhibits production of Th2-cytokines
by lymphoma cells in vitro [19]. It is also required for IL-12
secretion by antigen-presenting cells which pushes the
immune response towards the Th1 phenotype [20]. More-
over, the IFN-g induced up-regulation of expression of
the major histocompatibility complex molecules increases
the susceptibility of tumor cells to be recognized by the
host’s immune system [21]. Given these arguments, cuta-
neous lymphoma represents a good potential target for
adenovirus-mediated IFN-g gene delivery.
We analyzed the local immune infiltrates in injected
lesions obtained from advanced primary CTCL and multi-
lesional CBCL patients enrolled in the Phase I and II steps
of a clinical trial (Phase I/II study TG1042.01). Patients
received repeated intralesional injections of TG1042 and
we estimated the changes in the lymphocyte populations
at various timepoints throughout the study. We analyzed
the CD4 marker as characteristic of CTCL and the CD20
and CD79α markers as features of CBCL. The other
markers used in this study more generally define lympho-
cytic infiltration associated with an immune response:
CD3 for the complete T lymphocyte content, the CD8
marker is characteristic of effector Tcells and the cytotoxicity
marker protein TIA-1 contained in the granules in-
volved in lysis [22]. We also looked at MHC Class I ex-
pression since it is known to be induced by IFN-g and is
the target for cytotoxic T cells [21].
In the Per Protocol population of twenty evaluable
patients, only nineteen patients were evaluated in this
immunological study. Local clinical responses (Complete
and Partial Response) were observed in ten out of
nineteen (53%) patients. Four out of seven (57%) re-
sponding CTCL patients had stage IB or IIA disease at
baseline while five out of nine (55%) non-responders
(Stable and Progressive Disease) had stage IB disease at
inclusion. Although the limited number of patients in-
cluded in this work would not allow statistical analysis,
the equal distribution between responders and non-
responders tends to show that there is no association
between the stage of disease at baseline and the clinical
outcome following the treatment. This observation is
not applicable to CBCL patients because all patients are
complete responders.
It is interesting to note that for the CTCL from the
cohort 5, the histopathologist from the central labora-
tory (Dr Marie-Pierre Chenard at CHU Hautepierre,
Strasbourg, France) described the variation in size of the
lymphocytic infiltration either as increasing, unchanged or
decreasing and correlated the size of the infiltrates with
disease progression. Without knowing the nature of the
infiltrating cells, the pathologist described the responders
as “increased” or “unchanged” and the non- responders
as “unchanged” or “decreased” thereby associating complete
responses with important lymphocytic infiltration (data
not shown). This latter observation is in good agreement
with what we observed in the cohort of sixteen CTCL
patients studied here. For all the seven CTCL responders,
injection of TG1042 was associated with an increase in
CD8+ cells (100%). Five out of these seven patients had
increased numbers of TIA-1+ cells and one patient had
an increased intensity of MHC Class I from baseline
(11%). Five out of the nine CTCL non-responders have
an increased number of CD8+ cells (55%), four out of
these nine patients have a stable number of CD8+ cells
or no CD8+ cells, five out of nine had increased number
of TIA-1+ cells (56%) and two out of nine have an in-
creased intensity of MHC Class I staining (22%). Similar
results were seen in regressing CTCL tumors after intra-
lesional administration of IL-12 [14] or after injection
with adenovirus-engineered IL-2 expressing autologous
plasma cells [22]. Moreover, the CTCL complete re-
sponse correlate with a decrease in number of CD4+
cells reflecting the disappearance of lesions. Surpris-
ingly, although we expected IFN-g-mediated enhanced
MHC Class I expression, only three out of sixteen CTCL
showed an increased intensity of the MHC Class I staining
and no correlation with clinical responses. These results
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suggest that IFN-g promotes the development of cyto-
toxic CD8+ T cells-mediated immune responses directed
against the lymphoma cells [23,24].
Conclusion
In summary, intralesional injections of TG1042 (Adeno-
virus-IFN-g) induce changes in the nature of the in-
filtrate differing from the initial lymphoma. CBCL and
CTCL patients who responded had an increase in fre-
quency of CD8+ cells and TIA-1+ cells, indicative of an
immune response which is a critical component in the
antitumor response in lymphoma.
Consent
Prior to entering the study, patients were fully informed
orally and in writing about the objectives and implica-
tions of the study. They were informed that the data
disclosed in the reports and publications resulting from
the study would systematically be treated in an anonym-
ous manner, i.e. without identity revelation. All patients
provided written informed consent.
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Additional file 1: Table S1. Summary of immunostaining results.
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